Page last updated: 2024-11-07

mk 0663

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID123619
CHEMBL ID416146
CHEBI ID6339
SCHEMBL ID4680
MeSH IDM0402843

Synonyms (94)

Synonym
AB01275483-01
mk-663
arcoxia
nucoxia
tauxib
mk-0663
l-791456
D03710
etoricoxib (usan/inn)
l791456
etoricoxib ,
202409-33-4
5-chloro-6'-methyl-3-(p-(methylsulfonyl)phenyl)-2,3'-bipyridine
5-chloro-2-(6-methylpyridin-3-yl)-3-(4-(methylsulfonyl)phenyl)pyridine
DB01628
5-chloro-3-(4-methanesulfonyl-phenyl)-6'-methyl-[2,3']bipyridinyl
NCGC00164578-01
2,3'-bipyridine, 5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-
mk 663
mk 0663
etoricoxib [usan:inn:ban]
5ch ,
5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-2,3'-bipyridine
HMS2090A05
CHEBI:6339 ,
etoricoxibum
L001141
CHEMBL416146 ,
5-chloro-2-(6-methylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine
5-chloro-3-(4-methanesulfonyl-phenyl)-6''''-methyl-[2,3'''']bipyridinyl
5-chloro-3-(4-methanesulfonyl-phenyl)-6''-methyl-[2,3'']bipyridinyl
5-chloro-6''-methyl-3-[4-(methylsulfonyl)phenyl]-2,3''-bipyridine
bdbm50072064
dtxcid1026457
tox21_112206
dtxsid3046457 ,
cas-202409-33-4
S4651
AKOS016010125
algix
HY-15321
CS-1047
kingcox
torcoxia
unii-wrx4nfy03r
etropain
wrx4nfy03r ,
etoxib
etoricoxibe
FT-0602793
5-chloro-6'-methyl-3-(4-(methylsulfonyl)phenyl)-2,3'-bipyridine
etoricoxib [usan]
etoricoxib [inn]
etoricoxib [mart.]
etoricoxib [mi]
etoricoxib [who-dd]
gtpl2896
mk0663
BRD-K54770957-001-01-9
CCG-220639
SCHEMBL4680
tox21_112206_1
NCGC00164578-02
F2173-0490
tox21 112206
AC-29052
5-chloro-3-(4-methanesulfonylphenyl)-2-(6-methylpyridin-3-yl)pyridine
2,3'-bipyridine, 5-chloro-6'-methyl-3-[4-(methylsulfonyl)phenyl]-
mfcd06797512
SR-05000001486-2
sr-05000001486
etoricoxib, vetranal(tm), analytical standard
etoricoxib, united states pharmacopeia (usp) reference standard
SR-05000001486-1
J-013140
HMS3713P20
BCP06428
Q631202
FT-0668437
etoricoxib; mk-663; mk-0663
EX-A2642
5-chloro-6'-methyl-3-(4-(methylsulfonyl)-phenyl)-2,3'-bipyridine
AS-17761
BRD-K54770957-001-02-7
SB18988
HMS3885H14
AMY30994
mk-0663;l-791456
A848896
etoricoxib- bio-x
BC164436
EN300-18530864
5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-2,3'-bipyridine
Z2216907255

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Safety was assessed by adverse experiences (AEs) occurring during the trial."( Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
Antigua, J; Burton, R; Chen, E; Geba, GP; Londoño, J; Lund, M; Najarian, DK; Navarra, S; Ozturk, ZE; Petruschke, RA; Pryhuber, KG; Rubin, BR, 2004
)
0.32
" Etoricoxib was comparable in efficacy to indomethacin at a dosage of 50 mg 3 times daily, and it was generally safe and well tolerated."( Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
Antigua, J; Burton, R; Chen, E; Geba, GP; Londoño, J; Lund, M; Najarian, DK; Navarra, S; Ozturk, ZE; Petruschke, RA; Pryhuber, KG; Rubin, BR, 2004
)
0.32
"The use of selective inhibitors of cyclooxygenase 2 (COX-2) has been shown to be safe in patients with aspirin-induced asthma."( Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Caballero-Fonseca, F; Capriles-Hulett, A; Sánchez-Borges, M, 2005
)
0.33
" The most common adverse experiences were upper respiratory infection and headache."( Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy.
Curtis, SP; Eyster, ME; Giallella, KM; Melian, A; Mukhopadhyay, S; Reicin, AS; Shingo, S; Tsoukas, C, 2006
)
0.33
" Adverse events related to the use of the study medication in 1 and 3 months time were documented."( The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S, 2006
)
0.33
" For the patients who had to stop their drug therapy, all the adverse events occurred in the first month of drug/placebo challenge and all symptoms were reversible."( The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S, 2006
)
0.33
"Etoricoxib therapy is safe and beneficial in most patients with IBD treatment with etoricoxib was not associated with exacerbation of the underlying IBD- and GI-related complications."( The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S, 2006
)
0.33
" Etoricoxib was safe for treating inflammation in patients with AERD."( Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S, 2006
)
0.33
" Adverse experiences were collected for safety assessment."( Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
Bingham, CO; Bird, S; Fitzgerald, BJ; Kremer, J; O'Brien, K; Rubin, BR; Ruoff, GE; Sebba, AI; Smugar, SS; Tershakovec, AM, 2007
)
0.34
" Safety was assessed by observation of adverse experiences and laboratory and physical evaluations."( Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.
Bergman, G; Curtis, SP; Ko, AT; Malmstrom, K; Mehta, A; Reginster, JY; Reicin, AS, 2007
)
0.34
" The primary endpoint was the cumulative rate of discontinuations due to clinical and laboratory GI adverse experiences (AE)."( Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
Baraf, HS; Bird, S; Brzezicki, J; Curtis, SP; Fuentealba, C; Greenwald, M; Kaur, A; O'Brien, K; Polis, A; Soffer, B, 2007
)
0.34
"Cyclo-oxygenase (COX)-2 selective inhibitors (coxibs) were designed to reduce the incidence of gastrointestinal (GI) adverse events (AEs) which occur with non-selective NSAIDs (ns-NSAIDs)."( Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
Hunt, RH; Yuan, Y, 2007
)
0.34
" Although the use of selective inhibitors of cyclooxygenase (COX) 2 helps to prevent some of these adverse reactions, they can have cardiac side effects when taken for prolonged periods."( Safety of etoricoxib in patients with reactions to NSAIDs.
Emiliani, F; Foschi, FG; Quercia, O; Stefanini, GF, 2008
)
0.35
"We performed placebo-controlled oral challenge with etoricoxib in 65 patients with previous adverse reactions to NSAIDs: 13 to salicylates, 18 to arylpropionic acids, 10 to arylacetic acid, 12 to oxicam and derivates, 8 to pyrazolones, and 4 to acetaminophen (paracetamol)."( Safety of etoricoxib in patients with reactions to NSAIDs.
Emiliani, F; Foschi, FG; Quercia, O; Stefanini, GF, 2008
)
0.35
"Etoricoxib can be considered a safe molecule for those patients with previous adverse reactions to NSAIDs."( Safety of etoricoxib in patients with reactions to NSAIDs.
Emiliani, F; Foschi, FG; Quercia, O; Stefanini, GF, 2008
)
0.35
" Etoricoxib, a cox-2 inhibitor NSAID, has been shown to be a safe alternative in these patients."( Etoricoxib: a safe alternative for NSAID intolerance in Asian patients.
Cheng, YK; Gerez, IF; Llanora, GV; Loo, EX; Shek, LP, 2013
)
0.39
"Etoricoxib is a safe alternative in NSAID intolerant patients."( Etoricoxib: a safe alternative for NSAID intolerance in Asian patients.
Cheng, YK; Gerez, IF; Llanora, GV; Loo, EX; Shek, LP, 2013
)
0.39
" Our objective was to estimate and compare rates of gastrointestinal, renovascular, and cardiovascular adverse events in patients exposed to etoricoxib, celecoxib, or nonselective NSAIDs or totally unexposed to NSAIDs."( Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
Askling, J; Jacobsson, LT; Jakobsen, AK; Kristensen, LE; Nilsson, F, 2015
)
0.42
" No major risk differences for serious cardiovascular, gastrointestinal, or renal adverse events were seen among the 3 exposure groups."( Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
Askling, J; Jacobsson, LT; Jakobsen, AK; Kristensen, LE; Nilsson, F, 2015
)
0.42
"Overall, serious adverse events related to nonselective NSAIDs, etoricoxib, and celecoxib were similar and in the range of what would be expected in a group of SpA patients."( Safety of Etoricoxib, Celecoxib, and Nonselective Nonsteroidal Antiinflammatory Drugs in Ankylosing Spondylitis and Other Spondyloarthritis Patients: A Swedish National Population-Based Cohort Study.
Askling, J; Jacobsson, LT; Jakobsen, AK; Kristensen, LE; Nilsson, F, 2015
)
0.42
" The activity of axSpA (BASDAI, Ankylosing Spondylitis Disease Activity Score (ASDAS), erythrocyte sedimentation rate (ESR), and high-sensitivity C-reactive protein (hs-CRP)) was evaluated at baseline, 2 and 12 weeks; adverse events were recorded at baseline, 2, 6, and 12 weeks."( [Efficiency and safety of different etoricoxib regimens in patients with axial spondyloarthritis, including ankylosing spondylitis].
Gaydukova, IZ; Rebrov, AP, 2015
)
0.42
" All adverse events were recorded for safety assessment."( Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.
Liu, P; Ma, JL; Wang, J; Zhang, S; Zhang, W; Zhang, Y, 2016
)
0.43
"To ascertain if etoricoxib increases the risk of gastrointestinal adverse events (GAEs) compared with placebo, diclofenac, and naproxen in the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA)."( Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
Feng, X; Mei, H; Tian, M; Zhang, W, 2018
)
0.48
" These patients require an effective and safe analgesic alternative."( Meloxicam and/or Etoricoxib Could Be Administered Safely in Two Equal Doses during an Open Oral Challenge in Patients with Nonsteroidal Anti-Inflammatory Drug Hypersensitivity.
Martínez, DM; Ramírez Zuluaga, LF; Rojas-Mejía, DV; Serrano Reyes, CD; Silva Espinosa, DL, 2021
)
0.62
"Open oral provocation with meloxicam and etoricoxib carried out in 2 steps without placebo seems to be safe and implies less costs and less time expenditure."( Meloxicam and/or Etoricoxib Could Be Administered Safely in Two Equal Doses during an Open Oral Challenge in Patients with Nonsteroidal Anti-Inflammatory Drug Hypersensitivity.
Martínez, DM; Ramírez Zuluaga, LF; Rojas-Mejía, DV; Serrano Reyes, CD; Silva Espinosa, DL, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" There are no clinical or pharmacokinetic data in patients with severe hepatic insufficiency (Child-Pugh score > 9)."( Pharmacokinetics of etoricoxib in patients with hepatic impairment.
Agrawal, NG; Alam, I; Cote, J; Dilzer, SC; Geer, LA; Gottesdiener, KM; Larson, PJ; Lasseter, KC; Matthews, CZ; Petty, KJ; Porras, AG; Rose, MJ; Woolf, EJ, 2003
)
0.32
" Based on pharmacokinetic considerations, dosing adjustments are not necessary for patients with any degree of renal impairment."( Pharmacokinetics of etoricoxib in patients with renal impairment.
Agrawal, NG; Alcorn, H; Cho, M; Cote, J; Geer, LA; Gottesdiener, KM; Kline, WF; Marbury, TC; Matthews, CZ; Mazenko, RS; Moncrief, JW; Petty, KJ; Porras, AG; Robson, RA; Sack, MR; Schwartz, JI; Swan, S; Wong, PH; Woolf, EJ, 2004
)
0.32
"The effects of etoricoxib on pharmacodynamic and pharmacokinetic parameters of warfarin were determined in healthy men and women."( The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin.
Agrawal, NG; Cote, J; Eckols, DR; Gottesdiener, KM; Hartford, AH; Hunt, TL; Schwartz, JI; Verbesselt, R, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Plasma phenytoin levels were assayed by HPLC and pharmacokinetic parameters were calculated."( Effects of etoricoxib on the pharmacokinetics of phenytoin.
Bansal, V; Gaikwad, S; Medhi, B; Pandhi, P; Prakash, A; Sukhija, M,
)
0.13
" The elimination half-life of approximately 20 hours in healthy subjects enables once-daily dosing."( Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.
Davies, NM; Remsberg, CM; Reynolds, JK; Takemoto, JK; Vega-Villa, KR, 2008
)
0.35
"The aim of this study was to compare the pharmacokinetic properties of two etoricoxib (CAS 202409-33-4) 60 mg formulations, namely Etocox-60 (test product) and reference product, and to evaluate whether these two formulations meet the FDA criteria to assume bioequivalence."( Pharmacokinetic and bioequivalence study of etoricoxib tablet in healthy Bangladeshi volunteers.
Ahmed, MU; Hasanuzzaman, M; Hasnat, A; Islam, MS; Joti, JJ; Shohag, MH, 2011
)
0.37
" John's Wort (SJW), on its pharmacokinetic parameters and blood pressure was investigated in rats."( Pharmacokinetics and cardiovascular effect of etoricoxib in the absence or presence of St. John's Wort in rats.
Aboul-Enein, HY; Baky, NA; Radwan, MA; Zaghloul, I, 2012
)
0.38
" The main pharmacokinetic parameters of Cmax, tmax, t1/2, MRT, Vd, CL, and AUC were calculated by non-compartment model."( Pharmacokinetic and pharmacodynamic herb-drug interaction of Andrographis paniculata (Nees) extract and andrographolide with etoricoxib after oral administration in rats.
Atre, B; Balap, A; Lohidasan, S; Mahadik, K; Sinnathambi, A, 2016
)
0.43
" In pharmacodynamic study, ETO alone and ETO+APE (10+200mg/kg) groups exhibited significant synergistic anti-arthritic activity as compared to groups ETO+AN, APE and AN alone."( Pharmacokinetic and pharmacodynamic herb-drug interaction of Andrographis paniculata (Nees) extract and andrographolide with etoricoxib after oral administration in rats.
Atre, B; Balap, A; Lohidasan, S; Mahadik, K; Sinnathambi, A, 2016
)
0.43
"The results obtained from this study suggested that ETO, APE and pure AN existed pharmacokinetic herb-drug interactions in rat which is correlated with anti-arthritic study."( Pharmacokinetic and pharmacodynamic herb-drug interaction of Andrographis paniculata (Nees) extract and andrographolide with etoricoxib after oral administration in rats.
Atre, B; Balap, A; Lohidasan, S; Mahadik, K; Sinnathambi, A, 2016
)
0.43
" The validated method was applied in the pharmacokinetic study of etoricoxib in Chinese healthy volunteers under fed and fasted conditions."( Rapid quantitative analysis of etoricoxib in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in Chinese healthy volunteers.
Guo, N; Ji, W; Wen, Q; Zhang, X, 2019
)
0.51
" The elimination half-life was calculated to be 10."( Detection and Pharmacokinetics of Etoricoxib in Thoroughbred Horses.
Albert, PH; Kadry, AM; Singh, J; Subhahar, MB, 2020
)
0.56
" post-surgery celecoxib/etoricoxib/etodolac pharmacokinetic (PK) profiles."( Selective COX-2 inhibitors after bariatric surgery: Celecoxib, etoricoxib and etodolac post-bariatric solubility/dissolution and pharmacokinetics.
Cvijić, S; Dahan, A; Dukhno, O; Partook-Maccabi, M; Porat, D; Vainer, E, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" Therefore, the effect of pre-operative etoricoxib combined with local anaesthesia on post-operative pain and the discharge profile was studied in day-surgery patients undergoing arthroscopic shoulder surgery under general anaesthesia."( Etoricoxib pre-medication combined with intra-operative subacromial block for pain after arthroscopic acromioplasty.
Pitko, VM; Rosenberg, PH; Toivonen, J, 2007
)
0.34
"In patients having arthroscopic shoulder surgery under general anaesthesia combined with intra-operative subacromial regional analgesia, etoricoxib 120 mg reduced immediate and late post-operative pain, and facilitated early post-operative discharge."( Etoricoxib pre-medication combined with intra-operative subacromial block for pain after arthroscopic acromioplasty.
Pitko, VM; Rosenberg, PH; Toivonen, J, 2007
)
0.34
"This study has evaluated the anti-inflammatory and analgesic responses of etoricoxib, a selective COX-2 non-steroidal anti-inflammatory drug combined with misoprostol in pre-clinical assays."( Anti-inflammatory and analgesic actions of etoricoxib (an NSAID) combined with misoprostol.
Carvalho, JC; do Amaral, BC; Moraes, BM; Morimoto, MS; Perazzo, FF; Vieira, LG, 2007
)
0.34
"Management guidelines for drug-drug interactions between non-steroidal anti-inflammatory drugs (NSAIDs) and antihypertensives recommend blood pressure monitoring in hypertensive patients."( NSAID-antihypertensive drug interactions: which outpatients are at risk for a rise in systolic blood pressure?
Belitser, SV; Bouvy, ML; Buurma, H; De Smet, PA; Floor-Schreudering, A; Kramers, C; Tromp, PC, 2015
)
0.42
"Patients with a drug-drug interaction alert for a newly initiated NSAID and antihypertensive were interviewed and their SBP was measured at T0, after one week (T1) and after two weeks (T2)."( NSAID-antihypertensive drug interactions: which outpatients are at risk for a rise in systolic blood pressure?
Belitser, SV; Bouvy, ML; Buurma, H; De Smet, PA; Floor-Schreudering, A; Kramers, C; Tromp, PC, 2015
)
0.42
" Management guidelines for NSAID-antihypertensive drug-drug interactions should advise SBP monitoring before and after initiation of an NSAID or intensification of NSAID therapy."( NSAID-antihypertensive drug interactions: which outpatients are at risk for a rise in systolic blood pressure?
Belitser, SV; Bouvy, ML; Buurma, H; De Smet, PA; Floor-Schreudering, A; Kramers, C; Tromp, PC, 2015
)
0.42
"To evaluate the repairing effects of glucosamine sulfate combined with etoricoxib on articular cartilages of patients with knee osteoarthritis (KOA)."( Repairing effects of glucosamine sulfate in combination with etoricoxib on articular cartilages of patients with knee osteoarthritis.
Gong, C; Sun, Y; Wang, C, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"A method for the simultaneous determination of etoricoxib and its carbon-13 analog ((13)C(6)-etoricoxib) from human plasma has been developed and used to support bioavailability studies."( Simultaneous determination of unlabeled and carbon-13-labeled etoricoxib, a new cyclooxygenase-2 inhibitor, in human plasma using HPLC-MS/MS.
Agrawal, N; Matuszewski, BK; Rose, MJ; Woolf, EJ, 2002
)
0.31
" The oral dose, administered as a solution in polyethylene glycol-400, was well absorbed (absolute bioavailability of approximately 83%)."( Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
Agrawal, NG; Cui, D; Geer, LA; Gottesdiener, KM; Halpin, RA; Larson, PJ; Lasseter, KC; Matthews, CZ; Rodrigues, AD; Woolf, EJ, 2003
)
0.32
" Single-dose pharmacokinetics--including dose proportionality, absolute bioavailability of the highest dose-strength (120-mg) tablet, and the effect of a high-fat meal on the bioavailability of that tablet--were investigated in a two-part, open, balanced crossover study in two panels of healthy subjects (12 per panel)."( Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
Agrawal, NG; Dynder, AL; Gottesdiener, KM; Hunt, TL; Lasseter, KC; Matthews, CZ; Mazina, KE; McCrea, JB; Musser, BJ; Porras, AG; Rose, MJ; Schwartz, JI; Woolf, EJ, 2003
)
0.32
"The effect of Gelucire and polyvinylpyrrolidone (PVP) on stabilization and bioavailability of amorphous etoricoxib (AET) was studied."( Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13.
Chauhan, B; Mahadik, KR; Paradkar, A; Shimpi, SL, 2005
)
0.33
" Following oral administration, the less lipophilic celecoxib has a lower bioavailability (20-40%) than the other two coxibs (74-100%)."( Clinical use and pharmacological properties of selective COX-2 inhibitors.
Klotz, U; Shi, S, 2008
)
0.35
" The rate of absorption of etoricoxib is moderate when given orally (the maximum plasma drug concentration occurs after approximately 1 hour), and the extent of absorption is similar with oral and intravenous doses."( Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.
Davies, NM; Remsberg, CM; Reynolds, JK; Takemoto, JK; Vega-Villa, KR, 2008
)
0.35
"Etoricoxib is an anti-inflammatory drug largely used in a variety of acute and chronic inflammatory diseases, but is associated with low aqueous solubility and poor dissolution leading to a delayed rate of absorption and onset of action."( Development and pharmacological evaluation of cyclodextrin complexes of etoricoxib.
Arora, S; Kumar, P; Pahuja, S; Singh, I; Tung, V,
)
0.13
"1mg/kg for 7d/week (4) with serum bioavailability assessed by liquid chromatography-mass spectrometry."( Effects of the highly COX-2-selective analgesic NSAID etoricoxib on the rate of orthodontic tooth movement and cranial growth.
Kirschneck, C; Küchler, EC; Proff, P; Schröder, A; Wahlmann, U, 2018
)
0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" The profound inhibition of monocyte COX2 activity at 24 h after dosing, as predicted by a pharmacological half-life of approximately 22 h, supports a once-daily dosing regimen of etoricoxib."( Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.
Capone, ML; Patrignani, P; Tacconelli, S, 2003
)
0.32
" A high-fat meal decreased the rate of absorption without affecting the extent of absorption of etoricoxib; therefore, etoricoxib can be dosed irrespective of food."( Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
Agrawal, NG; Dynder, AL; Gottesdiener, KM; Hunt, TL; Lasseter, KC; Matthews, CZ; Mazina, KE; McCrea, JB; Musser, BJ; Porras, AG; Rose, MJ; Schwartz, JI; Woolf, EJ, 2003
)
0.32
" Multiple dosing of etoricoxib (up to 150 mg qd) showed no important effects on serum TXB2, bleeding time, or platelet aggregation (COX-1-mediated effects)."( Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
Agrawal, N; Dallob, A; De Schepper, P; DeTora, L; Gertz, B; Gottesdiener, K; Greenberg, H; Hawkey, CJ; Wagner, J; Waldman, S; Wight, N; Wong, P, 2003
)
0.32
" Together, these results support a 60-mg once-daily dosing regimen for mild hepatic insufficiency patients and a 60-mg every-other-day dosing regimen for moderate hepatic insufficiency patients."( Pharmacokinetics of etoricoxib in patients with hepatic impairment.
Agrawal, NG; Alam, I; Cote, J; Dilzer, SC; Geer, LA; Gottesdiener, KM; Larson, PJ; Lasseter, KC; Matthews, CZ; Petty, KJ; Porras, AG; Rose, MJ; Woolf, EJ, 2003
)
0.32
" Based on pharmacokinetic considerations, dosing adjustments are not necessary for patients with any degree of renal impairment."( Pharmacokinetics of etoricoxib in patients with renal impairment.
Agrawal, NG; Alcorn, H; Cho, M; Cote, J; Geer, LA; Gottesdiener, KM; Kline, WF; Marbury, TC; Matthews, CZ; Mazenko, RS; Moncrief, JW; Petty, KJ; Porras, AG; Robson, RA; Sack, MR; Schwartz, JI; Swan, S; Wong, PH; Woolf, EJ, 2004
)
0.32
"Etoricoxib at a dosage of 120 mg once daily was confirmed to be an effective treatment for acute gout."( Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
Antigua, J; Burton, R; Chen, E; Geba, GP; Londoño, J; Lund, M; Najarian, DK; Navarra, S; Ozturk, ZE; Petruschke, RA; Pryhuber, KG; Rubin, BR, 2004
)
0.32
"001); however, the rates of hypertension observed with etoricoxib at any dosage were not clinically meaningfully different versus comparator NSAIDs."( Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.
Bergman, G; Curtis, SP; McCormick, CL; Ng, J; Reicin, AS; Shingo, S; Yu, Q, 2004
)
0.32
" The recommended dosage of etoricoxib is 60 mg/day for osteoarthritis, 90 mg/day for rheumatoid arthritis and 120 mg/day for acute gouty arthritis."( [Etoricoxib (Arcoxia)].
Leclercq, P; Malaise, MG, 2004
)
0.32
" Fentanyl (in post-anesthesia care unit) and paracetamol (at home) were supplementary analgesics and the dosage was also recorded."( [Comparison of preemptive analgesia efficacy between etoricoxib and rofecoxib in ambulatory gynecological surgery].
Liu, W; Loo, CC; Ren, HZ; Tan, HM; Ye, TH, 2004
)
0.32
" Twice-daily dosage of aceclofenac 100 mg and etoricoxib 60 mg were recommended for the double blind study."( Comparative efficacy of aceclofenac and etoricoxib in post extraction pain control: randomized control trial.
Chalini, S; Raman, U,
)
0.13
"Reversed-phase liquid chromatography (LC) and LC/tandem mass spectrometry (LC/MS/MS) methods were developed and validated for the determination of etoricoxib in pharmaceutical dosage forms."( Validation of liquid chromatography and liquid chromatography/tandem mass spectrometry methods for the determination of etoricoxib in pharmaceutical formulations.
Barth, T; Brum, L; Ceni, DC; Dalmora, SL; Fronza, M,
)
0.13
"This multicenter, double-blind, randomized, placebo-controlled, parallel-group study assessed renal function during dosing with etoricoxib 90 mg daily, celecoxib 200 mg twice daily, and naproxen 500 mg twice daily."( Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet.
Gertz, BJ; Gottesdiener, KM; Hilliard, DA; Hreniuk, D; Lasseter, KC; Miller, J; Schwartz, JI; Snyder, KM; Thach, C, 2007
)
0.34
" It exhibited a significant analgesic effect in a guinea pig hyperalgesia model when orally dosed at 30 and 100mg/kg."( Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.
Boulet, L; Brideau, C; Claveau, D; Côté, B; Ducharme, Y; Ethier, D; Frenette, R; Friesen, RW; Gagnon, M; Giroux, A; Guay, J; Guiral, S; Mancini, J; Martins, E; Massé, F; Méthot, N; Riendeau, D; Rubin, J; Xu, D; Yu, H, 2007
)
0.34
"A CZE method was developed and validated for the analysis of etoricoxib in pharmaceutical dosage forms, using prilocaine as an internal standard."( Validation of a capillary zone electrophoresis method for the comparative determination of etoricoxib in pharmaceutical formulations.
Barth, T; da Silva, LM; Dalmora, SL; Macedo, RO; Sangoi, Mda S, 2008
)
0.35
" Information was sought from a dose-response trial over 6 weeks in osteoarthritis using placebo and using etoricoxib at 5, 10, 30 and 60 mg daily."( Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores.
Derry, S; McQuay, HJ; Moore, OA; Moore, RA, 2008
)
0.35
" The challenge was done using the placebo on the first day, half dosage of etoricoxib (45 mg) on the second day, and the therapeutic dose of 90 mg on the third day."( Safety of etoricoxib in patients with reactions to NSAIDs.
Emiliani, F; Foschi, FG; Quercia, O; Stefanini, GF, 2008
)
0.35
" In vitro results combined with in silico simulations using GastroPlus support scientifically that a biowaiver for immediate release etoricoxib solid oral dosage forms is justified."( Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products.
DiMaso, M; Löbenberg, R; Okumu, A, 2009
)
0.35
"A new, simple HPTLC method for determination of etoricoxib (ETO) and thiocolchicoside (THIO) in combined tablet dosage form has been developed and validated."( High-performance thin-layer chromatographic determination of etoricoxib and thiocolchicoside in combined tablet dosage form.
Gandhi, SV; Patil, UP; Rajmane, VS; Sengar, MR,
)
0.13
" An ibuprofen dosage of 1,600 mg/day did not induce LUF syndrome either at continuous periovulatory or discontinuous exposure."( Luteinized unruptured follicle syndrome increased by inactive disease and selective cyclooxygenase 2 inhibitors in women with inflammatory arthropathies.
Micu, MC; Micu, R; Ostensen, M, 2011
)
0.37
"A simple, reproducible and efficient reverse phase high performance liquid chromatographic method was developed for simultaneous estimation of etoricoxib and thiocolchicoside in combined tablet dosage form."( Simultaneous estimation of etoricoxib and thiocolchicoside by RP-HPLC method in combined dosage forms.
Joshi, A; Kumar, S; Pathak, AK; Shah, K; Thakur, RS,
)
0.13
" Rats' blood pressures were monitored initially, after 1 and 3 weeks of treatment, and after 1 week of discontinuing dosing of both drugs."( Pharmacokinetics and cardiovascular effect of etoricoxib in the absence or presence of St. John's Wort in rats.
Aboul-Enein, HY; Baky, NA; Radwan, MA; Zaghloul, I, 2012
)
0.38
"In patients undergoing total abdominal hysterectomy, etoricoxib 90 mg and 120 mg dosed preoperatively and then continued postoperatively significantly reduces both resting and movement-related pain, as well as reduced opioid (morphine) consumption that led to more rapid bowel recovery."( Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study.
Curtis, SP; Frenkl, TL; Gammaitoni, A; Hartrick, CT; Kehlet, H; Ko, AT; Mehta, A; Morgan, LM; Papanicolaou, D; Peloso, PM; Rawal, N; Viscusi, ER, 2012
)
0.38
" Patients were allowed flexible dosing on days 2 and 3; 46, 96, 190, 192, and 56 patients on placebo, etoricoxib 120 mg, etoricoxib 90 mg, ibuprofen, and A/C, respectively, continued to Day 2 of the study."( Evaluation of multiday analgesia with etoricoxib in a double-blind, randomized controlled trial using the postoperative third-molar extraction dental pain model.
Bandy, DP; Boice, JA; Brown, JD; Daniels, SE; Gammaitoni, A; Ko, AT; Losada, MC; Mehta, A; Peloso, PM, 2013
)
0.39
" Depending on the type and level of change and the BCS class of the molecule, dissolution data and/or bioequivalence (BE) may be needed to support the change for immediate release dosage forms."( Application of absorption modeling to predict bioequivalence outcome of two batches of etoricoxib tablets.
Dogterom, P; Kesisoglou, F; Mitra, A, 2015
)
0.42
"An etoricoxib-induced clinically relevant deceleration of OTM is not to be expected at dosage regimens used in clinical practice to treat dental or orthodontic pain in contrast to a continuously administered high dosage."( Effects of the highly COX-2-selective analgesic NSAID etoricoxib on the rate of orthodontic tooth movement and cranial growth.
Kirschneck, C; Küchler, EC; Proff, P; Schröder, A; Wahlmann, U, 2018
)
0.48
"Considering significant results for some measures of the variable edema for the group that used intramuscular dexamethasone and the difference without statistical significance between groups for the other variables studied, we seem to reflect the intramuscular indication of the corticosteroid in a single dosage in relation to the use of etoricoxib as pre-emptive medication."( Effect of preemptive dexamethasone and etoricoxib on postoperative period following impacted third molar surgery - a randomized clinical trial.
Pereira, GS; Ribeiro, RC; Rodrigues, ÉD; Vasconcelos, BC, 2019
)
0.51
"Fixed-dose combinations (FDCs) refer to products containing two or more active ingredients combined in a single dosage form."( A Critical Review on Analytical Methods for Recently Approved FDC Drugs: Pregabalin and Etoricoxib.
Kotadiya, R; Shah, J, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
cyclooxygenase 2 inhibitorA cyclooxygenase inhibitor that interferes with the action of cyclooxygenase 2.
non-steroidal anti-inflammatory drugAn anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
sulfoneAn organosulfur compound having the structure RS(=O)2R (R =/= H).
bipyridinesCompounds containing a bipyridine group.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Etoricoxib Action Pathway2967

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency33.22110.002541.796015,848.9004AID1347395; AID1347398
TDP1 proteinHomo sapiens (human)Potency24.23070.000811.382244.6684AID686978; AID686979
progesterone receptorHomo sapiens (human)Potency33.49150.000417.946075.1148AID1346784
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency24.96380.01237.983543.2770AID1346984; AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.68320.000214.376460.0339AID720691
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.84930.001530.607315,848.9004AID1224849
cytochrome P450 2D6Homo sapiens (human)Potency17.37680.00108.379861.1304AID1645840
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency36.12540.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency0.00080.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.70790.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)53.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)49.10000.11007.190310.0000AID1443980; AID1473738
Prostaglandin G/H synthase 1Ovis aries (sheep)IC50 (µMol)30.00000.00032.177410.0000AID1637762
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)62.40000.00021.557410.0000AID161500; AID1751818; AID1751820; AID241307; AID432546
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)0.45860.00010.995010.0000AID1358184; AID1532170; AID162483; AID162637; AID1751817; AID1751819; AID241308; AID432545
Prostaglandin G/H synthase 2Homo sapiens (human)Ki0.06900.00050.41861.5000AID1751838
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)0.23000.00101.453910.0000AID1637763
Mitogen-activated protein kinase 14Homo sapiens (human)IC50 (µMol)0.53000.00010.72667.8000AID241942
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (162)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipopolysaccharideMitogen-activated protein kinase 14Homo sapiens (human)
DNA damage checkpoint signalingMitogen-activated protein kinase 14Homo sapiens (human)
cell morphogenesisMitogen-activated protein kinase 14Homo sapiens (human)
cartilage condensationMitogen-activated protein kinase 14Homo sapiens (human)
angiogenesisMitogen-activated protein kinase 14Homo sapiens (human)
osteoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
placenta developmentMitogen-activated protein kinase 14Homo sapiens (human)
response to dietary excessMitogen-activated protein kinase 14Homo sapiens (human)
chondrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusMitogen-activated protein kinase 14Homo sapiens (human)
glucose metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
apoptotic processMitogen-activated protein kinase 14Homo sapiens (human)
chemotaxisMitogen-activated protein kinase 14Homo sapiens (human)
signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
cell surface receptor protein serine/threonine kinase signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
skeletal muscle tissue developmentMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of gene expressionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myotube differentiationMitogen-activated protein kinase 14Homo sapiens (human)
peptidyl-serine phosphorylationMitogen-activated protein kinase 14Homo sapiens (human)
fatty acid oxidationMitogen-activated protein kinase 14Homo sapiens (human)
platelet activationMitogen-activated protein kinase 14Homo sapiens (human)
regulation of ossificationMitogen-activated protein kinase 14Homo sapiens (human)
osteoclast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated protein kinase signaling cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cyclase activityMitogen-activated protein kinase 14Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
response to muramyl dipeptideMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of interleukin-12 productionMitogen-activated protein kinase 14Homo sapiens (human)
response to insulinMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of hippo signalingMitogen-activated protein kinase 14Homo sapiens (human)
intracellular signal transductionMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to vascular endothelial growth factor stimulusMitogen-activated protein kinase 14Homo sapiens (human)
response to muscle stretchMitogen-activated protein kinase 14Homo sapiens (human)
p38MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of protein import into nucleusMitogen-activated protein kinase 14Homo sapiens (human)
signal transduction in response to DNA damageMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of erythrocyte differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIMitogen-activated protein kinase 14Homo sapiens (human)
glucose importMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of glucose importMitogen-activated protein kinase 14Homo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
stem cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
striated muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of muscle cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
stress-activated MAPK cascadeMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of cardiac muscle cell proliferationMitogen-activated protein kinase 14Homo sapiens (human)
bone developmentMitogen-activated protein kinase 14Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to lipoteichoic acidMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to tumor necrosis factorMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to ionizing radiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to UV-BMitogen-activated protein kinase 14Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of brown fat cell differentiationMitogen-activated protein kinase 14Homo sapiens (human)
cellular senescenceMitogen-activated protein kinase 14Homo sapiens (human)
stress-induced premature senescenceMitogen-activated protein kinase 14Homo sapiens (human)
cellular response to virusMitogen-activated protein kinase 14Homo sapiens (human)
regulation of synaptic membrane adhesionMitogen-activated protein kinase 14Homo sapiens (human)
regulation of cytokine production involved in inflammatory responseMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of myoblast fusionMitogen-activated protein kinase 14Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processMitogen-activated protein kinase 14Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
protein serine/threonine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
MAP kinase kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
ATP bindingMitogen-activated protein kinase 14Homo sapiens (human)
enzyme bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein phosphatase bindingMitogen-activated protein kinase 14Homo sapiens (human)
mitogen-activated protein kinase p38 bindingMitogen-activated protein kinase 14Homo sapiens (human)
NFAT protein bindingMitogen-activated protein kinase 14Homo sapiens (human)
protein serine kinase activityMitogen-activated protein kinase 14Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (39)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
spindle poleMitogen-activated protein kinase 14Homo sapiens (human)
extracellular regionMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
nucleoplasmMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
mitochondrionMitogen-activated protein kinase 14Homo sapiens (human)
cytosolMitogen-activated protein kinase 14Homo sapiens (human)
nuclear speckMitogen-activated protein kinase 14Homo sapiens (human)
secretory granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
glutamatergic synapseMitogen-activated protein kinase 14Homo sapiens (human)
ficolin-1-rich granule lumenMitogen-activated protein kinase 14Homo sapiens (human)
nucleusMitogen-activated protein kinase 14Homo sapiens (human)
cytoplasmMitogen-activated protein kinase 14Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (154)

Assay IDTitleYearJournalArticle
AID1751838Inhibition of human recombinant COX-2 using arachidonic acid as substrate preincubated for 60 mins followed by substrate addition for 2 secs by ADPH based fluorometric analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID265686Inhibition of adjuvant-induced arthritis in Wistar rat at 1 mg/kg, po2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID432546Inhibition of human COX1 expressed in african green monkey COS cells assessed as inhibition of arachidonic acid-stimulated PGE2 treated 1 hr before arachidonic acid challenge by enzyme immunoassay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
AID268044Selectivity ratio for COX2 over COX1 in human whole blood2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
AID1667982Inhibition of human recombinant COX-2 at 100 uM using arachidonic acid as substrate preincubated for 15 mins followed by substrate addition and measured after 5 mins by ADPH-based fluorescence assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Anti-inflammatory effect and inhibition of nitric oxide production by targeting COXs and iNOS enzymes with the 1,2-diphenylbenzimidazole pharmacophore.
AID1637763Inhibition of ovine COX2 using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition and measured after 2 mins by ELISA2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID265682Stability in rat liver microsomes2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1751829Drug concentration in C57BL/6J mouse plasma at 10 mg/kg, po administered as cassette dose measured at 4 hrs by LC/MS/MS analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1667986Inhibition of iNOS in mouse macrophages assessed as reduction in LPS-induced nitric oxide production at 50 uM incubated for overnight by griess assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Anti-inflammatory effect and inhibition of nitric oxide production by targeting COXs and iNOS enzymes with the 1,2-diphenylbenzimidazole pharmacophore.
AID265691Tmax in Wistar rat at 1 mg/kg, po2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID244252Selectivity for Prostaglandin G/H synthase 2 (COX-2) and Prostaglandin G/H synthase 1 (COX-1) in human whole blood as ratio of IC502005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID161500Inhibition of Prostaglandin G/H synthase 1 was measured by the inhibition of PGE-2 produced by microsomes from U937 cells at subsaturating arachidonic acid conc.1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.
AID1751817Inhibition of COX2 (unknown origin) expressed in HEK293 TRex cells assessed as reduction in PGE2 production using arachidonic acid as substrate preincubated for 60 mins followed by substrate addition for 1 hr in presence of 10% FBS by RapidFire High-Throu2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1751820Inhibition of COX1 (unknown origin) expressed in HEK293 TRex cells assessed as reduction in PGE2 production using arachidonic acid as substrate preincubated for 60 mins followed by substrate addition for 1 hr in presence of 10% FBS by RapidFire High-Throu2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID432545Inhibition of human COX2 expressed in african green monkey COS cells assessed as inhibition of arachidonic acid-stimulated PGE2 production treated 1 hr before arachidonic acid challenge by enzyme immunoassay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1751826Volume of distribution at steady state in C57BL/6J mouse at 2 mg/kg, iv measured after 0.08 to 24 hrs2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1358196Anticonvulsant activity in Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 10 mg/kg, ip administered 4 hrs prior to PTZ challenge and measured after 30 mins2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID1358206Antiepileptic activity in rat model of PTZ-induced epileptiogenesis kindling model assessed as decrease of seizure severity at 5 mg/kg, ip measured up to 28 days2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID1637774Anti-inflammatory activity in human erythrocytes assessed as inhibition of hypotonicity-induced hemolysis at 100 ug/ml relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID241307Inhibition of human cyclooxygenase-1 expressed in COS cells2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
AID242133In vitro inhibitory concentration against Prostaglandin G/H synthase 2 (COX-2) in human whole blood2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
AID1667988Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema formation at 100 mg/kg, po administered 1 hr before carrageenan stimulation and measured after up to 6 hrs relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Anti-inflammatory effect and inhibition of nitric oxide production by targeting COXs and iNOS enzymes with the 1,2-diphenylbenzimidazole pharmacophore.
AID1751830Ratio of drug concentration in C57BL/6J mouse colon to plasma at 10 mg/kg, po measured after 4 hr by liquid chromatographic triple-quadrupole mass spectrometric method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1751849Selectivity ratio of IC50 for COX1 (unknown origin) expressed in HEK293 TRex cells assessed as reduction in PGE2 production to IC50 for COX2 (unknown origin) expressed in HEK293 TRex cells assessed as reduction in PGE2 production2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID178405Effective dose in the yeast-induced pyresis model in rat2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.
AID317361Inhibition of LPS-stimulated PGE2 production in human whole blood2007Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24
Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors.
AID1637771Anti-inflammatory activity in human erythrocytes assessed as inhibition of hypotonicity-induced hemolysis at 10 ug/ml relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID1751851Protein occupancy at human recombinant COX-2 assessed as dissociation half life2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1751818Inhibition of human recombinant COX-1 assessed as reduction in peroxidase activity using arachidonic acid as substrate preincubated for 60 mins followed by substrate addition for 2 secs by ADPH based fluorometric analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID162637Inhibition of Prostaglandin G/H synthase 2 was measured by the inhibition of PGE-2 produced by lipopolysaccharide-challenged HWB1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.
AID432551Inhibition of COX2 in human whole blood assessed as inhibition of lipopolysaccharide-stimulated PGE2 production after 24 hrs by enzyme immunoassay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
AID432547Selectivity ratio of IC50 for human COX1 to IC50 for human COX2 expressed in african green monkey COS cells2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
AID1667987Inhibition of iNOS in mouse macrophages assessed as reduction in LPS-induced nitric oxide production at 100 uM incubated for overnight by griess assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Anti-inflammatory effect and inhibition of nitric oxide production by targeting COXs and iNOS enzymes with the 1,2-diphenylbenzimidazole pharmacophore.
AID1751853Inhibition of COX1 in human whole blood assessed as reduction in calcium ionophore-stimulated TXB2 production incubated for 1 hr by ELISA2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID268051Activity against adjuvant-induced arthritis in po dosed Wistar rat2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
AID1532170Inhibition of human COX-2 transfected in CHO cells using arachidonic acid as substrate2019European journal of medicinal chemistry, Jan-15, Volume: 162Medicinal chemistry of vicinal diaryl scaffold: A mini review.
AID1358189Anticonvulsant activity in Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 5 mg/kg, ip administered 0.5 hrs prior to PTZ challenge and measured after 30 mins2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID1751831Tmax in C57BL/6J mouse at 10 mg/kg, po administered as cassette dose measured at 4 hrs by liquid chromatographic triple-quadrupole mass spectrometric method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID161497Inhibition concentration against cyclooxygenase-1 (COX-1) in human whole blood2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.
AID1751819Inhibition of human recombinant COX-2 assessed as reduction in peroxidase activity using arachidonic acid as substrate preincubated for 60 mins followed by substrate addition for 2 secs by ADPH based fluorometric analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1637776Anti-inflammatory activity Wistar rat assessed as inhibition of carrageenan-induced paw edema at 25 to 50 mg/kg pretreated 30 mins prior to carrageenan-induction and measured after 24 hrs by plethysmography2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID1751857Equilibrium solubility of compound in in FASSIF at pH 6.52021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1637772Anti-inflammatory activity in human erythrocytes assessed as inhibition of hypotonicity-induced hemolysis at 25 ug/ml relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID1751852Inhibition of COX2 in human whole blood assessed as reduction in LPS stimulated PGE2 production incubated for 1 hr by ELISA2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1358184Inhibition of human recombinant COX2 using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition and measured after 2 mins by ADPH probe-based fluorescence assay2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID1637770Anti-inflammatory activity in human erythrocytes assessed as inhibition of heat-induced hemolysis at 100 ug/ml relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID252095In vivo antiinflammatory potency in rat air pouch model expressed as inhibition of PGE-2 production following oral dosage of 5.4 mg/kg (15 mmol)2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
AID1358188Anticonvulsant activity in Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 1 mg/kg, ip administered 0.5 hrs prior to PTZ challenge and measured after 30 mins2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID241942Inhibitory concentration against p38 alpha MAP kinase calculated by CoMFA model; FlexX score = -18.6kcal/mol 2005Bioorganic & medicinal chemistry letters, Aug-01, Volume: 15, Issue:15
The molecular basis for coxib inhibition of p38alpha MAP kinase.
AID241308Inhibition of human cyclooxygenase-2 expressed in COS cells2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
AID1751869Selectivity ratio of IC50 for COX1 in human whole blood assessed as reduction in calcium ionophore-stimulated TXB2 production to IC50 for COX2 in human whole blood assessed as reduction in LPS stimulated PGE2 production2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID766004Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 0.05 mmol/kg, po administered 30 mins prior challenge measured after 5 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis, antiproliferative and anti-inflammatory activities of some novel 6-aryl-2-(p-(methanesulfonyl)phenyl)-4,5-dihydropyridazi-3(2H)-ones.
AID265681Stability in human liver microsomes2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID265680Selectivity for COX2 over COX12006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID162483In vitro inhibition of PGE-2 produced by arachidonic acid-stimulated CHO cells stably expressing human Prostaglandin G/H synthase 21998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.
AID1751854Protein binding in human plasma assessed as unbound fraction2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1751862Antitumor activity in C57BL/6J mouse model of spontaneous GI-tract tumor Apc-min assessed as reduction in total ileum polyp area at 300 mg/kg, po administered as suspension for 10 to 12 weeks2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID766005Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 0.05 mmol/kg, po administered 30 mins prior challenge measured after 3 hrs2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis, antiproliferative and anti-inflammatory activities of some novel 6-aryl-2-(p-(methanesulfonyl)phenyl)-4,5-dihydropyridazi-3(2H)-ones.
AID268052Inhibition of yeast-induced pyresis in Wistar rat2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
AID432552Inhibition of COX1 in human whole blood assessed as inhibition of lipopolysaccharide-induced TxB2 production after 30 min by enzyme immunoassay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
AID1667981Inhibition of bovine COX1 at 100 uM using arachidonic acid as substrate preincubated for 5 mins followed by substrate addition and measured after 5 mins by ADPH-based fluorescence assay relative to control2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Anti-inflammatory effect and inhibition of nitric oxide production by targeting COXs and iNOS enzymes with the 1,2-diphenylbenzimidazole pharmacophore.
AID1751822Half life in mouse liver microsomes2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID177072Efficacy in rat paw edema assay upon oral administration.1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.
AID162633Inhibition concentration against cyclooxygenase-2 (COX-2) in human whole blood2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.
AID1358194Anticonvulsant activity in Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 1 mg/kg, ip administered 4 hrs prior to PTZ challenge and measured after 30 mins2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID252110In vivo antiinflammatory potency in rat air pouch model expressed as inhibition of white blood cell infiltration following oral dosage of 5.4 mg/kg (15 mmol)2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
AID177073Efficacy in rat pyresis assay upon oral administration1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.
AID265684Solubility in PBS at pH 7.22006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID162664In vitro inhibition of Prostaglandin G/H synthase 2 in human whole blood assay2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).
AID265693AUC(0-t) in Wistar rat at 1 mg/kg, po2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID1751858Drug concentration in C57BL/6J mouse portal vein plasma at 10 mg/kg, po administered as cassette dose measured at 4 hrs by LC/MS/MS analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID178664Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using preventive method; dose administered daily twice2004Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4
In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives.
AID265679Inhibition of COX2 in human whole blood2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID1751856Apparent permeability across apical to basolateral side in MDCK-MDR1 cells in presence of P-gp inhibitor2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1637780Analgesic activity in Wistar rat assessed as reduction in acetic acid-induced abnormal writhing administered intraperitoneally 1 hr prior to acetic acid induction relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID1751825Clearance in C57BL/6J mouse at 2 mg/kg, iv measured after 0.08 to 24 hrs2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1637768Anti-inflammatory activity in human erythrocytes assessed as inhibition of heat-induced hemolysis at 25 ug/ml relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID246823Reduced Freund's complete adjuvant (FCA)-induced arthritis in rats2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
AID1358190Anticonvulsant activity in Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 10 mg/kg, ip administered 0.5 hrs prior to PTZ challenge and measured after 30 mins2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID1637762Inhibition of ovine COX1 using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition and measured after 2 mins by ELISA2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID1751824Half life in mouse hepatocytes2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1751823Half life in human hepatocytes2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID242132In vitro inhibitory concentration against Prostaglandin G/H synthase 1 (COX-1) in human whole blood2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
3-[4-(methylsulfonyl)phenyl]-5-(trifluoromethyl)(2-pyridyl) phenyl ketone as a potent and orally active cyclooxygenase-2 selective inhibitor: synthesis and biological evaluation.
AID161673In vitro inhibition of Prostaglandin G/H synthase 1 in human whole blood assay2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).
AID1751860Chemo-protective activity in C57BL/6J mouse model of spontaneous GI-tract tumor Apc-min assessed as 18F-FDG uptake in ileum at 300 mg/kg, po incorporated into chow diet administered daily for 2 weeks and measured after 14 days by ex vivo PET imaging analy2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1751827Half life in C57BL/6J mouse at 2 mg/kg, iv measured after 0.08 to 24 hrs2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1637767Anti-inflammatory activity in human erythrocytes assessed as inhibition of heat-induced hemolysis at 10 ug/ml relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1637773Anti-inflammatory activity in human erythrocytes assessed as inhibition of hypotonicity-induced hemolysis at 50 ug/ml relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID244091Ratio of IC50 for human COX-1 and COX-22004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID178404Effective dose in the adjuvant induced arthritis model in rat2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.
AID47556Inhibition of cytochrome P450 CYP3A4 in human liver microsomes2001Bioorganic & medicinal chemistry letters, Apr-23, Volume: 11, Issue:8
In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).
AID1358195Anticonvulsant activity in Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizures at 5 mg/kg, ip administered 4 hrs prior to PTZ challenge and measured after 30 mins2018European journal of medicinal chemistry, May-10, Volume: 151Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation.
AID232654Ratio of inhibitory activity against cyclooxygenase- (COX-1) to that of cyclooxygenase- (COX-2)2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.
AID265683Solubility in SGF at pH 1.82006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID265688Inhibition of yeast-induced pyresis in Wistar rat at 3 mg/kg, po2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID1637769Anti-inflammatory activity in human erythrocytes assessed as inhibition of heat-induced hemolysis at 50 ug/ml relative to control2019MedChemComm, Mar-01, Volume: 10, Issue:3
Rationally synthesized coumarin based pyrazolines ameliorate carrageenan induced inflammation through COX-2/pro-inflammatory cytokine inhibition.
AID11597Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr1998Bioorganic & medicinal chemistry letters, Oct-06, Volume: 8, Issue:19
2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: selective and orally active cyclooxygenase-2 inhibitors.
AID1751859Ratio of drug concentration in C57BL/6J mouse colon to portal vein plasma at 10 mg/kg, po measured after 4 hr by liquid chromatographic triple-quadrupole mass spectrometric method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID432553Selectivity ratio of IC50 for COX1 to IC50 for COX2 in human whole blood2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Identification of [4-[4-(methylsulfonyl)phenyl]-6-(trifluoromethyl)-2-pyrimidinyl] amines and ethers as potent and selective cyclooxygenase-2 inhibitors.
AID1667983Selectivity index, ratio of inhibition of human recombinant COX-2 at 100 uM to inhibition of bovine COX-1 at 100 uM2020Bioorganic & medicinal chemistry, 05-01, Volume: 28, Issue:9
Anti-inflammatory effect and inhibition of nitric oxide production by targeting COXs and iNOS enzymes with the 1,2-diphenylbenzimidazole pharmacophore.
AID538646Inhibition of mPGES1 mediated PGE2 production in LPS stimulated human whole blood by EIA2010Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23
Biarylimidazoles as inhibitors of microsomal prostaglandin E2 synthase-1.
AID265689Cmax in Wistar rat at 1 mg/kg, po2006Bioorganic & medicinal chemistry letters, Jun-15, Volume: 16, Issue:12
Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
AID1751828Drug concentration in C57BL/6J mouse colon at 10 mg/kg, po administered as cassette dose measured at 4 hrs by LC/MS/MS analysis2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1751821Half life in human liver microsomes2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID1751863Antitumor activity in C57BL/6J mouse model of spontaneous GI-tract tumor Apc-min assessed as mouse survival at 100 mg/kg, po administered daily as suspension and measured at day 82 by Kaplan-Meier method2021Journal of medicinal chemistry, 08-12, Volume: 64, Issue:15
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer.
AID183368In vivo inhibition of hyperalgesia in rat at 3 mg/kg2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Synthesis and biological evaluation of 2-phenylpyran-4-ones: a new class of orally active cyclooxygenase-2 inhibitors.
AID268043Inhibition of COX2 in human whole blood2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Racemic and chiral sulfoxides as potential prodrugs of 4-pyrone COX-2 inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID493017Wombat Data for BeliefDocking2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Identification of 2,3-diaryl-pyrazolo[1,5-b]pyridazines as potent and selective cyclooxygenase-2 inhibitors.
AID1345206Human COX-2 (Cyclooxygenase)2001The Journal of pharmacology and experimental therapeutics, Feb, Volume: 296, Issue:2
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (511)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (0.20)18.2507
2000's206 (40.31)29.6817
2010's230 (45.01)24.3611
2020's74 (14.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.33 (24.57)
Research Supply Index6.58 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials173 (31.51%)5.53%
Reviews63 (11.48%)6.00%
Case Studies56 (10.20%)4.05%
Observational4 (0.73%)0.25%
Other253 (46.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]